Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2016-11-04

FDA Approved: ALECENSA — Supplemental Application (Genentech, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for ALECENSA (alectinib hydrochloride) to update the label for its use in ALK-positive non-small cell lung cancer, r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Alecensa (alectinib)

Snippet

SUPPL AP for ALECENSA (ALECTINIB HYDROCHLORIDE)